KT103

KT103 is an investigational drug candidate being developed by Keren Therapeutics for sarcopenia and potentially other age-related or nervous system disorders. Publicly accessible information is very limited, but secondary pipeline sources describe it as a preclinical asset with no disclosed molecular target, mechanism of action, modality, formulation, or administration route. Keren Therapeutics has publicly described its broader platform as leveraging the biology of osteocalcin and related peptide hormone biology to restore muscle function and address cognitive decline, but a direct, source-verifiable linkage of KT103 itself to a specific osteocalcin-based construct, target, or mechanism has not been clearly established from the available evidence.